Book contents
- A Tattoo on My Brain
- Reviews
- A Tattoo on My Brain
- Copyright page
- Dedication
- Contents
- Acknowledgments
- Introduction
- Prologue
- 1 Beacon Rock
- 2 Forewarned and Forearmed
- 3 The Smell of Baking Bread
- 4 Sneak Preview
- 5 A Stubborn Puzzle
- 6 The Locked Box and the Family Tree
- 7 The Measure of Memory
- 8 Orcas Nonetheless
- 9 My Brain, My Self
- 10 The Reveal
- 11 Cognitive Reserve and Resiliency: Brain Cells in the Bank
- 12 My Experimental Life
- 13 When ARIA Is More than an Operatic Solo
- 14 My Experiential Life: Living with Early-Stage Alzheimer’s Disease
- 15 Madeleines, Music and African Doves
- 16 It’s Only Scary If You Look Down
- 17 Beyond DNA: Family History Reconsidered
- 18 News at 5: Retired Neurologist Battles Alzheimer’s
- 19 The Forest, the Trees and the Ground Beneath My Feet
- 20 What’s in a Name? Alzheimer’s Reimagined
- 21 A Meaningful Outcome
- Epilogue: The Writing Life
- Epilogue: The Writing Life, Act II
- Appendix:
- Resources
- Index
- References
20 - What’s in a Name? Alzheimer’s Reimagined
Published online by Cambridge University Press: 12 November 2022
Book contents
- A Tattoo on My Brain
- Reviews
- A Tattoo on My Brain
- Copyright page
- Dedication
- Contents
- Acknowledgments
- Introduction
- Prologue
- 1 Beacon Rock
- 2 Forewarned and Forearmed
- 3 The Smell of Baking Bread
- 4 Sneak Preview
- 5 A Stubborn Puzzle
- 6 The Locked Box and the Family Tree
- 7 The Measure of Memory
- 8 Orcas Nonetheless
- 9 My Brain, My Self
- 10 The Reveal
- 11 Cognitive Reserve and Resiliency: Brain Cells in the Bank
- 12 My Experimental Life
- 13 When ARIA Is More than an Operatic Solo
- 14 My Experiential Life: Living with Early-Stage Alzheimer’s Disease
- 15 Madeleines, Music and African Doves
- 16 It’s Only Scary If You Look Down
- 17 Beyond DNA: Family History Reconsidered
- 18 News at 5: Retired Neurologist Battles Alzheimer’s
- 19 The Forest, the Trees and the Ground Beneath My Feet
- 20 What’s in a Name? Alzheimer’s Reimagined
- 21 A Meaningful Outcome
- Epilogue: The Writing Life
- Epilogue: The Writing Life, Act II
- Appendix:
- Resources
- Index
- References
Summary
Early in my career, when I chose to step away from research and devote my career to clinical neurology, one of the most compelling reasons was how much I loved working directly with patients, able to bring cutting-edge medical approaches to them and see the difference these made in their lives. When I was in medical school, somebody once told me that his father had been a neurologist but had left to go into research because patients were disheartening – there was so little to be done for so many. That was true up to about the 1980s. But by the time I went into practice, that had changed. It was an especially exciting time to be a neurologist because advances in research were producing medications that could dramatically improve a number of these conditions. The advances in medical treatment of migraine and MS had been life-changing for so many of my patients. Unfortunately, dementia was not one of those scientific success stories – at least, not then.
- Type
- Chapter
- Information
- A Tattoo on my BrainA Neurologist's Personal Battle against Alzheimer's Disease, pp. 168 - 177Publisher: Cambridge University PressPrint publication year: 2023
References
Chapter-references
Irizarry, MC, Jin, S, He, F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Archives of Neurology 2012; 69:368–372; https://doi.org/10.1001/archneurol.2011.830 (public access version available at www.ncbi.nlm.nih.gov/pmc/articles/PMC3622046).CrossRefGoogle ScholarPubMed
Vossel, KA, Beagle, AJ, Rabinovici, G, et al. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurology 2013; 70:1158–1166; https://doi.org/10.1001/jamaneurol.2013.136 (public access version available at www.ncbi.nlm.nih.gov/pmc/articles/PMC4013391).CrossRefGoogle ScholarPubMed
Crutch, SJ, Lehmann, M, Schott, JM, et al. Posterior cortical atrophy. Lancet Neurology 2012; 11:170–178; https://doi.org/10.1016/S1474-4422(11)70289-7 (public access version available at www.ncbi.nlm.nih.gov/pmc/articles/PMC3740271).CrossRefGoogle ScholarPubMed
Salloway, S, Sperling, R, Fox, NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. New England Journal of Medicine 2014; 370:322–333 (public access version available at www.ncbi.nlm.nih.gov/pmc/articles/PMC4159618).CrossRefGoogle ScholarPubMed
Knopman, DS. Sifting through a failed Alzheimer trial: what biomarkers tell us about what happened. Neurology 2018; 90:447–448; https://doi.org/10.1212/WNL.0000000000005073.CrossRefGoogle ScholarPubMed
Yin, J, Reiman, EM, Beach, TG, et al. Effect of ApoE isoforms on mitochondria in Alzheimer disease. Neurology 2020; 94:e2404–e2411; https://doi.org/10.1212/WNL.0000000000009582.CrossRefGoogle ScholarPubMed
Arboleda-Velasquez, JF, Lopera, F, O’Hare, M, et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nature Medicine 2019; 25:1680–1683; https://doi.org/10.1038/s41591-019–0611-3 (public access version available at www.ncbi.nlm.nih.gov/pmc/articles/PMC6898984).CrossRefGoogle Scholar
Espay, A, Stecher, B. Brain Fables: The Hidden History of Neurodegenerative Diseases and a Blueprint to Conquer Them. Cambridge University Press, 2020.CrossRefGoogle Scholar
Che´telat, G, La Joie, R, Villain, N, et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer’s disease. NeuroImage: Clinical, 2013; 2:356–365; https://doi.org/10.1016/j.nicl.2013.02.006 (public access version available at www.ncbi.nlm.nih.gov/pmc/articles/PMC3777672).CrossRefGoogle ScholarPubMed
Palmqvist, S, Janelidze, S, Quiroz, YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 2020; 324:772–781; https://doi.org/10.1001/jama.2020.12134 (public access version available at https://jamanetwork.com/journals/jama/fullarticle/2768841).CrossRefGoogle Scholar